Issue link: https://www.e-digitaleditions.com/i/1546950
News on R&D and progress in the treatment of respiratory diseases, such as asthma and COPD, as well as articles on food allergy, air quality, public health, etc. Calendar: The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. 38 OctOber 2026 Inhalation rization for EURneffy ® 1 mg in the UK for the treatment of ana- phylaxis in children aged 4 years and older, weighing 15 kg to less than 30 kg, living with severe allergies. EURneffy 1 mg is indi- cated for the emergency treat- ment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal prod- ucts and other allergens, as well as idiopathic or exercise-induced anaphylaxis. e approval follows the existing UK marketing autho- rization for EURneffy 2 mg, pre- viously approved by the MHRA for the emergency treatment of anaphylaxis in adults and children weighing greater than or equal to 30 kg. e company noted that EURneffy is the first and only needle- free adrenaline treatment and extends a class of treatment previously available only by injec- tion. "For decades, children at risk of anaphylaxis have been limited to injectable adrenaline—yet fear of needles, hesitancy to act and incorrect administration mean adrenaline is too often not car- ried or used in time," said Flora Beiche-Scholz, EVP Commercial Operations Europe, ALK. "is approval brings us closer to ensur- ing every family affected by severe allergies has a treatment they will actually carry and use." CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations Nemera ® launches bidose nasal spray LYON, FRANCE— Nemera ® a n n o u n c e d t h e l a u n c h o f DuoSpray™, a bidose nasal spray platform designed to support nasal drug-device combination product development for systemic drug administration. According to a com- pany news release, the launch reflects Nemera's strategy to provide phar- maceutical companies with flexible, commercially ready platform solu- tions that help accelerate the adop- tion of systemic intranasal therapies. DuoSpray complements Nemera's commercially available UniSpray™ platform. Together they offer options for systemic, intra-mucosal nasal administration, with format selec- tion depending on drug volume, posology, intended use and product- specific development strategy. While UniSpray supports unidose applica- tions, ideally suited for life-saving and crisis applications, DuoSpray delivers two metered doses within a single device, for acute therapies. e news release noted Nemera's plat- form approach supports emerging and established nasal administration of systemic therapies, including inno- vative drugs, repurposed molecules and generics, while offering flexibility throughout the product lifecycle. "By combining complementary liquid platforms with expanding dry pow- der capabilities, we are building a comprehensive portfolio of intranasal solutions that helps pharmaceutical companies bring innovative therapies to patients faster and with reduced development risk," said Dimitri Grasswill, Vice President Ear, Nose and roat (ENT), Nemera. RESPIRATORY MEDICINE NEWS MHRA approves EURneffy ® for children ages 4 and older HØRSHOLM, DENMARK— ALK announced that the Med- icines and Healthcare products Regulatory Agency (MHRA) has granted marketing autho- Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR ® Inha- lation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Phar- maceutical Products R&D LLC (West Chester, Pennsylvania, US). A company news release explained the product is Aurobindo's first metered dose inhaler (MDI), mark- ing a milestone in its expansion into complex respiratory therapies and strengthening its capabilities in the inhalation segment. In addition, the release noted that Beclomethasone Dipropionate HFA Inhalation Aero- sol is indicated in the maintenance treatment of asthma as prophylac- tic therapy in patients 5 years of age and older. It is also indicated for asthma patients who require systemic corticosteroid adminis- tration, where adding Beclometha- sone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for systemic corticosteroids. ADVERTISER INDEX B Bespak 5 C Copley Scientific 3 D DDL 1 M MG America Cover 2 P Proveris Laboratories 9 R RDD 23 S S-Matrix 7 INDUSTRY NEWS continued from page 8

